Neurocrine Biosciences (FRA:NB3) Accounts Payable & Accrued Expense : €213 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Accounts Payable & Accrued Expense?

Neurocrine Biosciences's quarterly accounts payable & accrued expense declined from Sep. 2023 (€299 Mil) to Dec. 2023 (€284 Mil) and declined from Dec. 2023 (€284 Mil) to Mar. 2024 (€213 Mil).

Neurocrine Biosciences's annual accounts payable & accrued expense increased from Dec. 2021 (€144 Mil) to Dec. 2022 (€204 Mil) and increased from Dec. 2022 (€204 Mil) to Dec. 2023 (€284 Mil).

Neurocrine Biosciences Accounts Payable & Accrued Expense Historical Data

The historical data trend for Neurocrine Biosciences's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Accounts Payable & Accrued Expense Chart

Neurocrine Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

99.63

110.23

144.34

203.62

283.81

Neurocrine Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															332.22	361.45	299.00	283.81	212.80

Neurocrine Biosciences Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Neurocrine Biosciences (FRA:NB3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (FRA:NB3) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

NBIX:USA N1BI34:Brazil

Address

12780 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (FRA:NB3) Headlines

No Headlines